Clinical trial
An Open-label, Multi-center Phase II Clinical Study on the Efficacy and Safety of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT05563844 is registered in ClinicalTrials.gov with Chengdu Zenitar Biomedical Technology Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Multi-center Phase II Clinical Study on the Efficacy and Safety of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Lead sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- November 8, 2022
- Completion date
- December 1, 2027
- Enrollment
- 74 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
diffuse large b cell lymphoma，dlbcl